influenza virus neuraminidase
E414768
Influenza virus neuraminidase is a surface enzyme on influenza viruses that enables the release and spread of new viral particles from infected cells and is a key target of antiviral drugs.
All labels observed (1)
| Label | Occurrences |
|---|---|
| influenza virus neuraminidase canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4131831 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: influenza virus neuraminidase Context triple: [oseltamivir, hasTarget, influenza virus neuraminidase]
-
A.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
B.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
C.
Fluzão
Fluzão is a popular nickname for Fluminense Football Club, one of Brazil’s traditional Rio de Janeiro–based football teams.
-
D.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
E.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: influenza virus neuraminidase Target entity description: Influenza virus neuraminidase is a surface enzyme on influenza viruses that enables the release and spread of new viral particles from infected cells and is a key target of antiviral drugs.
-
A.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
B.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
C.
Fluzão
Fluzão is a popular nickname for Fluminense Football Club, one of Brazil’s traditional Rio de Janeiro–based football teams.
-
D.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
E.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
drug target
ⓘ
enzyme ⓘ sialidase ⓘ viral surface glycoprotein ⓘ |
| antigenicSubtype |
N1
ⓘ
N2 ⓘ N3 ⓘ N4 ⓘ N5 ⓘ N6 ⓘ N7 ⓘ N8 ⓘ N9 ⓘ |
| biologicalProcess |
cleavage of sialic acid from host cell surface receptors
ⓘ
prevention of virion aggregation ⓘ viral release from host cell ⓘ viral spread in respiratory epithelium ⓘ |
| catalyzes | hydrolysis of terminal sialic acid residues from glycoproteins and glycolipids ⓘ |
| cellularLocation |
viral envelope
ⓘ
virion surface ⓘ |
| encodedBy | influenza virus NA gene ⓘ |
| evolvesBy |
antigenic drift
ⓘ
reassortment of NA gene segment ⓘ |
| formsComplexWith | influenza virus hemagglutinin on virion surface ⓘ |
| foundInTaxon |
influenza A virus
ⓘ
influenza B virus ⓘ influenza C virus ⓘ |
| hasActiveSiteResidue |
arginine triad in catalytic site
ⓘ
tyrosine 406 (in N2 numbering) ⓘ |
| hasDomain |
globular head domain
ⓘ
stalk domain ⓘ |
| hasMolecularFunction |
exosialidase activity
ⓘ
glycosidase activity ⓘ |
| hasQuaternaryStructure | homotetramer ⓘ |
| hasStructure | six-bladed beta-propeller fold in globular head ⓘ |
| isAntigenOf |
influenza A virus N subtypes
ⓘ
influenza B virus neuraminidase antigen ⓘ |
| isComponentOf | influenza virus envelope protein coat ⓘ |
| isTargetOf |
laninamivir
ⓘ
neuraminidase inhibitor class antivirals ⓘ neutralizing antibodies ⓘ oseltamivir ⓘ peramivir ⓘ zanamivir ⓘ |
| postTranslationalModification | N-linked glycosylation ⓘ |
| roleInDisease | contributes to pathogenicity of influenza infection ⓘ |
| substrate |
neuraminic acid residues
ⓘ
sialic acid-containing receptors ⓘ |
| usedFor | subtyping of influenza A viruses ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: influenza virus neuraminidase Description of subject: Influenza virus neuraminidase is a surface enzyme on influenza viruses that enables the release and spread of new viral particles from infected cells and is a key target of antiviral drugs.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.